Acquired Company

Social Capital Suvretta Holdings Corp. III completed its business combination with ProKidney on 7/12/2022, and the combined company began trading as ProKidney Corp. on Nasdaq under the symbol PROK.

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Show more

2000 Frontis Plaza Blvd., Winston-Salem, NC, 27103, United States

https://prokidney.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

649.8M

52 Wk Range

$0.46 - $7.13

Previous Close

$2.16

Open

$2.15

Volume

753,658

Day Range

$2.15 - $2.26

Enterprise Value

84.97M

Cash

271.7M

Avg Qtr Burn

-26.6M

Insider Ownership

25.38%

Institutional Own.

34.59%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rilparencel (REACT®) Details Chronic kidney disease, Diabetes	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.